Serina Therapeutics (SER): SEC Form 3 filed by new insider Simon Farrell
Stocks in this Quantisnow insightHealth Care
Historical context for SER
Across the 19 sessions after earlier SER headlines, the stock closed higher 8 times and lower 11 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SER | SPY |
|---|---|---|---|
| Jul 23, 2026 | Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Diseaseand 1 other headline that session | -3.7% | -1.2% |
| Jul 9, 2026 | Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease | +10.0% | +0.8% |
| Jul 1, 2026 | BTIG Research initiated coverage on Serina Therapeutics with a new price target | -1.0% | -0.1% |
| Jun 30, 2026 | Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program | -1.5% | +0.8% |
| May 15, 2026 | Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | -4.7% | -1.2% |
| Apr 7, 2026 | Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit | -3.3% | +0.0% |
Quantisnow market dataAMEX
SER
Serina Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for SER
Full SER profile on Quantisnow Follow SER and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time